Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)

Next Previous
Search
Trial Profile

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Isotretinoin; Methotrexate; Methylprednisolone; Mycophenolate mofetil; Tacrolimus
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Aug 2021 Status changed from active, no longer recruiting to completed.
    • 07 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
    • 04 Dec 2019 Planned End Date changed from 1 Mar 2018 to 1 Jan 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top